Stockscreener 앱 받기
120.56
10.42%
11.38
시장 영업 전:
126.50
5.94
+4.93%
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Belite Bio (NASDAQ:BLTE) Earns Neutral Rating from Analysts at Mizuho - Defense World
Belite Bio’s Stock Dips Amid Analyst Caution - TipRanks
Mizuho initiates Belite Bio stock coverage with Neutral rating ahead of key trial data - Investing.com Canada
Will Belite Bio Inc Depositary Receipt stock sustain high P E ratiosTrade Exit Summary & Consistent Return Investment Signals - newser.com
Belite Bio stock reaches all-time high at 125.0 USD By Investing.com - Investing.com South Africa
Belite Bio stock reaches all-time high at 125.0 USD - Investing.com
Belite Bio ADR’s Earnings Call: Progress Amid Rising Costs - MSN
Dry Age-related Macular Degeneration Market Poised for Rapid Growth During the Forecast Period (2025–2034) Amid Expanding Treatment Landscape | DelveInsight - GlobeNewswire Inc.
(BLTE) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Belite Bio (NASDAQ:BLTE) Cut to Sell at Wall Street Zen - Defense World
Using data tools to time your Belite Bio Inc Depositary Receipt exitBear Alert & Real-Time Volume Surge Alerts - newser.com
Promising Outlook for Belite Bio’s Tinlarebant Drives Buy Rating Amidst Strong Financial Position and Regulatory Support - TipRanks
Belite Bio Advances in Retinal Disease Therapeutics - MSN
Belite Bio (NASDAQ:BLTE) Stock Price Down 8.2% Following Weak Earnings - Defense World
Why Belite Bio Inc (Common Stock) (D01) stock is listed among top recommendationsJuly 2025 PostEarnings & Weekly Market Pulse Alerts - newser.com
Belite Bio reports Q3 EPS (65c), consensus (49c) - TipRanks
Belite Bio Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Belite Bio Q3 2025 reports increased R&D expenses - Investing.com India
Belite Bio, Inc. ADR Shares Surge Amid Trial Success - TipRanks
Belite Bio stock reaches all-time high at 117.95 USD By Investing.com - Investing.com Canada
Belite Bio stock reaches all-time high at 117.95 USD - Investing.com
Earnings Flash (BLTE) Belite Bio Posts Q3 Net Loss $0.65 a Share, vs. FactSet Est. of $0.45 Loss - MarketScreener
Belite Bio Announces Q3 2025 Results and Key Trial Progress - TipRanks
Belite Bio Q3 net loss widens on higher R&D expenses - MarketScreener
Belite Bio (NASDAQ: BLTE) NMPA, MHRA accept Tinlarebant; closes $125M private placement - Stock Titan
Belite Bio (BLTE) to Release Quarterly Earnings on Monday - Defense World
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to ... - Black Hills Pioneer
Understanding Belite Bio Inc Depositary Receipt’s price movementJobs Report & Technical Pattern Based Buy Signals - newser.com
Belite Bio (BLTE) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Exact Sciences (EXAS) Gets a Buy from Benchmark Co. - The Globe and Mail
Analyzing Belite Bio Inc Depositary Receipt with multi timeframe chartsWeekly Market Outlook & Low Volatility Stock Suggestions - newser.com
Cash per share of Belite Bio, Inc. ADR – SWB:D01 - TradingView
Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference 2025, Nov-04-2025 10 - MarketScreener
Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference 2025Slideshow - Seeking Alpha
Belite Bio (NASDAQ:BLTE) Stock Price Up 7.3% Following Analyst Upgrade - MarketBeat
Belite Bio (NASDAQ:BLTE) Hits New 52-Week HighShould You Buy? - MarketBeat
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results - GlobeNewswire
Belite Bio Recieves UK Acceptance for Conditional Approval of Stargardt Disease Drug - MarketScreener
Belite Bio (NASDAQ: BLTE) to host third-quarter results webcast at 4:30 p.m. ET - Stock Titan
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of... - markets.businessinsider.com
Belite Bio Announces UK’s Medicines and Healthcare Products - GlobeNewswire
MHRA Agrees to Accept CMA for Tinlarebant — Belite Bio (BLTE); DRAGON topline Q4 2025 - Stock Titan
Belite Bio (NASDAQ:BLTE) Stock Price Expected to Rise, Benchmark Analyst Says - MarketBeat
Belite Bio stock hits all-time high at 101.92 USD By Investing.com - Investing.com Australia
Belite Bio stock hits all-time high at 101.92 USD - Investing.com
Can machine learning forecast Belite Bio Inc Depositary Receipt recoveryIndex Update & Consistent Growth Equity Picks - newser.com
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighTime to Buy? - MarketBeat
Benchmark Co. Reaffirms Their Hold Rating on NeoGenomics (NEO) - The Globe and Mail
How Belite Bio Inc Depositary Receipt stock performs during Fed tightening cyclesJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Belite Bio to Present at the dbVICDeutsche Bank ADR Virtual Investor Conference November 4th - GlobeNewswire
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference - GlobeNewswire
How Belite Bio Inc (Common Stock) (D01) stock valuation compares with sectorJuly 2025 Update & Reliable Entry Point Trade Alerts - Fundação Cultural do Pará
Risk vs reward if holding onto Belite Bio Inc Depositary ReceiptJuly 2025 Breakouts & Free Verified High Yield Trade Plans - newser.com
Why Belite Bio Inc Depositary Receipt stock could benefit from AI revolution2025 Sector Review & Daily Oversold Bounce Ideas - newser.com
Belite Bio (NASDAQ:BLTE) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Will Belite Bio Inc (Common Stock) (D01) stock outperform energy sector in 2025Earnings Trend Report & Stepwise Entry and Exit Trade Signals - newser.com
1.38%
1.42%
자본화:
|
볼륨(24시간):